Stryker (SYK) Expected to Post Earnings on Thursday

Stryker (NYSE:SYK) will likely be issuing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of $3.49 per share and revenue of $6.5802 billion for the quarter. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the business earned $2.84 EPS. On average, analysts expect Stryker to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Stryker Stock Performance

Shares of SYK opened at $309.50 on Thursday. Stryker has a 1 year low of $281.00 and a 1 year high of $404.87. The stock has a market capitalization of $118.65 billion, a PE ratio of 35.82, a PEG ratio of 2.02 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock has a 50-day simple moving average of $313.94 and a 200-day simple moving average of $335.90.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 40.74%.

Wall Street Analyst Weigh In

Several research analysts have commented on SYK shares. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a report on Friday, May 1st. Wells Fargo & Company reduced their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Barclays decreased their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. Truist Financial reiterated a “hold” rating and set a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Finally, Needham & Company LLC cut their price target on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $392.52.

Insider Activity at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 in the last three months. 4.60% of the stock is currently owned by company insiders.

Institutional Trading of Stryker

Several institutional investors and hedge funds have recently bought and sold shares of the business. Rossby Financial LCC raised its holdings in shares of Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares in the last quarter. Tcfg Wealth Management LLC boosted its position in shares of Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after acquiring an additional 29 shares during the last quarter. Sompo Asset Management Co. Ltd. grew its holdings in shares of Stryker by 1.3% in the second quarter. Sompo Asset Management Co. Ltd. now owns 2,390 shares of the medical technology company’s stock valued at $946,000 after purchasing an additional 30 shares in the last quarter. CYBER HORNET ETFs LLC increased its position in Stryker by 3.3% in the third quarter. CYBER HORNET ETFs LLC now owns 931 shares of the medical technology company’s stock worth $344,000 after purchasing an additional 30 shares during the last quarter. Finally, Sittner & Nelson LLC increased its position in Stryker by 0.3% in the third quarter. Sittner & Nelson LLC now owns 11,770 shares of the medical technology company’s stock worth $4,351,000 after purchasing an additional 35 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.